A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer.
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Orteronel (Primary) ; Bicalutamide; LHRH receptor agonists
- Indications Prostate cancer
- Focus Therapeutic Use
- 14 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Mar 2022.
- 04 Oct 2016 Planned number of patients changed from 1486 to 1304.